MA51530A - Composés cycliques fondus - Google Patents
Composés cycliques fondusInfo
- Publication number
- MA51530A MA51530A MA051530A MA51530A MA51530A MA 51530 A MA51530 A MA 51530A MA 051530 A MA051530 A MA 051530A MA 51530 A MA51530 A MA 51530A MA 51530 A MA51530 A MA 51530A
- Authority
- MA
- Morocco
- Prior art keywords
- cyclic compounds
- molten cyclic
- molten
- compounds
- cyclic
- Prior art date
Links
- 150000001923 cyclic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018114788 | 2018-11-09 | ||
| EP19842848.4A EP3735299B1 (fr) | 2018-11-09 | 2019-11-08 | Composés cycliques fondus |
| PCT/US2019/060578 WO2020097537A2 (fr) | 2018-11-09 | 2019-11-08 | Composés cycliques fondus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA51530A true MA51530A (fr) | 2021-04-21 |
| MA51530B1 MA51530B1 (fr) | 2024-12-31 |
Family
ID=69232886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA51530A MA51530B1 (fr) | 2018-11-09 | 2019-11-08 | Composés cycliques fondus |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US11236068B2 (fr) |
| EP (2) | EP3735299B1 (fr) |
| JP (4) | JP6941241B2 (fr) |
| KR (3) | KR20250012188A (fr) |
| CN (5) | CN112105419B (fr) |
| AR (1) | AR117194A1 (fr) |
| AU (3) | AU2019377130B2 (fr) |
| BR (1) | BR112021008986A2 (fr) |
| CA (1) | CA3087089C (fr) |
| CL (2) | CL2021001171A1 (fr) |
| CO (1) | CO2021005987A2 (fr) |
| CR (1) | CR20210229A (fr) |
| DK (1) | DK3735299T3 (fr) |
| ES (1) | ES3004042T3 (fr) |
| FI (1) | FI3735299T3 (fr) |
| HR (1) | HRP20241581T1 (fr) |
| HU (1) | HUE069365T2 (fr) |
| IL (3) | IL282916B2 (fr) |
| LT (1) | LT3735299T (fr) |
| MA (1) | MA51530B1 (fr) |
| MX (5) | MX2021005428A (fr) |
| MY (1) | MY196726A (fr) |
| PE (2) | PE20260440A1 (fr) |
| PH (1) | PH12021551065A1 (fr) |
| PL (1) | PL3735299T3 (fr) |
| PT (1) | PT3735299T (fr) |
| RS (1) | RS66280B1 (fr) |
| SG (1) | SG11202103298QA (fr) |
| SI (1) | SI3735299T1 (fr) |
| SM (1) | SMT202400487T1 (fr) |
| TW (2) | TWI784209B (fr) |
| UA (1) | UA127930C2 (fr) |
| WO (1) | WO2020097537A2 (fr) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195609A2 (fr) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulateurs de protéolyse et procédés d'utilisation associés |
| WO2020085504A1 (fr) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | Procédé de production d'un dérivé de carboxylate de chloroazole par réaction de sandmeyer avec exposition à la lumière |
| CN114437065A (zh) | 2019-05-21 | 2022-05-06 | 益方生物科技(上海)股份有限公司 | 杂环化合物，其制备方法和用途 |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| UA129778C2 (uk) | 2019-10-28 | 2025-07-30 | Мерк Шарп Енд Доум Елелсі | Низькомолекулярні інгібітори g12c-мутантного kras |
| EP4065231A1 (fr) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Inhibiteurs de ras covalents et leurs utilisations |
| EP4067343A4 (fr) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | Nouveau composé phénolique ou sel de celui-ci |
| WO2021120045A1 (fr) | 2019-12-18 | 2021-06-24 | InventisBio Co., Ltd. | Composés hétérocycliques, leurs procédés de préparation et utilisations associées |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| IL300309B2 (en) * | 2020-08-12 | 2026-03-01 | Genentech Inc | Synthesis of quinazoline compounds |
| TW202220994A (zh) * | 2020-08-17 | 2022-06-01 | 大陸商貝達藥業股份有限公司 | 雙環化合物，包含其的藥物組合物及其用途 |
| CA3191279A1 (fr) | 2020-08-28 | 2022-03-03 | Yi Liu | Composes heterocycliques et leurs utilisations |
| US20250195521A1 (en) | 2020-09-03 | 2025-06-19 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| EP4210833A4 (fr) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | Formes cristallines d'un inhibiteur de kras g12c |
| JP2023544450A (ja) | 2020-09-23 | 2023-10-23 | エラスカ・インコーポレイテッド | 三環式ピリドン及びピリミドン |
| WO2022068921A1 (fr) * | 2020-09-30 | 2022-04-07 | 上海医药集团股份有限公司 | Composé quinazoline et son application |
| WO2022098625A1 (fr) * | 2020-11-03 | 2022-05-12 | Mirati Therapeutics, Inc. | Inhibiteurs de kras g12d |
| TWI886356B (zh) * | 2020-11-13 | 2025-06-11 | 美商建南德克公司 | 用於治療實性瘤之方法與包含ｋｒａｓｇ１２ｃ抑制劑及ｖｅｇｆ抑制劑之組成物 |
| EP4243827A1 (fr) * | 2020-11-13 | 2023-09-20 | Genentech, Inc. | Méthodes et compositions comprenant un inhibiteur de krasg12c et un antagoniste de liaison pd-l1 pour le traitement du cancer du poumon |
| WO2022105855A1 (fr) * | 2020-11-20 | 2022-05-27 | Jacobio Pharmaceuticals Co., Ltd. | Inhibiteurs de kras g12d |
| CN116490508A (zh) * | 2020-11-20 | 2023-07-25 | 北京加科思新药研发有限公司 | Kras g12d抑制剂 |
| CA3204191A1 (fr) * | 2020-12-08 | 2022-06-16 | Genentech, Inc. | Methodes et compositions comprenant un inhibiteur de krasg12c et un inhibiteur d'egfr pour traiter des tumeurs solides |
| JP2023553492A (ja) | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| EP4262803A4 (fr) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Inhibiteurs pan-kras de tétrahydropyridopyrimidine |
| CA3203080A1 (fr) * | 2020-12-22 | 2022-06-30 | Hongqi Tian | Preparation et procede d'application d'un compose heterocyclique utilise en tant qu'inhibiteur de kras |
| CN113999226B (zh) * | 2020-12-22 | 2023-01-06 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| CN114685532A (zh) * | 2020-12-31 | 2022-07-01 | 正大天晴药业集团股份有限公司 | 大环类化合物及其医药用途 |
| EP4291199A4 (fr) * | 2021-02-09 | 2025-06-18 | Kumquat Biosciences Inc. | Composés hétérocycliques et leurs utilisations |
| WO2022171013A1 (fr) * | 2021-02-09 | 2022-08-18 | 南京明德新药研发有限公司 | Composé de tétrahydroquinazoline |
| WO2022171018A1 (fr) * | 2021-02-09 | 2022-08-18 | 苏州泽璟生物制药股份有限公司 | Inhibiteur d'amine de benzopyrimidine ou de pyridopyrimidine substitué, son procédé de préparation et son utilisation |
| CA3210167A1 (fr) * | 2021-02-09 | 2022-08-18 | Genentech, Inc. | Composes d'oxazepine tetracycliques et leurs utilisations |
| BR112023016299A2 (pt) * | 2021-02-16 | 2023-11-28 | L Livermore Nat Security Llc | Composições e métodos para inibir kras |
| US20250255868A1 (en) * | 2021-04-09 | 2025-08-14 | Hangzhou Innogate Pharma Co., Ltd. | Heterocyclic compound acting as kras g12d inhibitor |
| WO2022221386A1 (fr) * | 2021-04-14 | 2022-10-20 | Erasca, Inc. | Inhibiteurs sélectifs de kras |
| EP4322954A4 (fr) * | 2021-04-16 | 2025-01-29 | Merck Sharp & Dohme LLC | Inhibiteurs à petites molécules de mutant de kras g12d |
| US20250059205A1 (en) * | 2021-04-29 | 2025-02-20 | Amgen Inc. | Heterocyclic Compounds and Methods of Use |
| JP2024516450A (ja) * | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ｒａｓ阻害剤及びその使用 |
| JP2024519845A (ja) * | 2021-05-19 | 2024-05-21 | ジェネンテック， インコーポレイテッド | 併用療法 |
| US20240300980A1 (en) * | 2021-05-22 | 2024-09-12 | Shanghai Kechow Pharma, Inc. | Heterocyclic compounds as kras inhibitor, and preparation therefor and use thereof in treatment |
| US20240261444A1 (en) * | 2021-05-26 | 2024-08-08 | Cornell University | Rigidified macrocycles, complexes with radionuclides, and use in targeted radiotherapy of cancer |
| IL310291A (en) | 2021-07-23 | 2024-03-01 | Theras Inc | Compositions and methods for inhibition of ras |
| CN117858878A (zh) * | 2021-08-18 | 2024-04-09 | 北京加科思新药研发有限公司 | N-环丙基吡啶并[4,3-d]嘧啶-4-胺衍生物及其用途 |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| KR20240055778A (ko) | 2021-09-01 | 2024-04-29 | 노파르티스 아게 | Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도 |
| EP4436571A4 (fr) * | 2021-11-24 | 2025-10-15 | Merck Sharp & Dohme Llc | Petites molécules inhibitrices de protéines à mutation kras |
| US12110276B2 (en) | 2021-11-24 | 2024-10-08 | Genentech, Inc. | Pyrazolo compounds and methods of use thereof |
| US12275745B2 (en) | 2021-11-24 | 2025-04-15 | Genentech, Inc. | Therapeutic compounds and methods of use |
| TW202340202A (zh) | 2021-12-22 | 2023-10-16 | 美國加利福尼亞大學董事會 | Gtp酶抑制劑及其用途 |
| AR128211A1 (es) * | 2022-01-06 | 2024-04-10 | Theras Inc | Composiciones y métodos para la inhibición de ras |
| AR128212A1 (es) * | 2022-01-06 | 2024-04-10 | Theras Inc | Composiciones y métodos para la inhibición de ras |
| JP2025505655A (ja) * | 2022-02-07 | 2025-02-28 | ジェネンテック， インコーポレイテッド | １－（（ｓ）－４－（（ｒ）－７－（６－アミノ－４－メチル－３－（トリフルオロメチル）ピリジン－２－イル）－６－クロロ－８－フルオロ－２－（（（ｓ）－１－メチルピロリジン－２－イル）メトキシ）キナゾリン－４－イル）－３－メチルピペラジン－１－イル）プロパ－２－エン－１－オンの固体形態 |
| US12071422B2 (en) * | 2022-02-07 | 2024-08-27 | Genentech, Inc. | Process for synthesis of quinazoline compounds |
| AU2023231139A1 (en) | 2022-03-11 | 2024-09-05 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| EP4473970A4 (fr) | 2022-03-31 | 2026-01-21 | Eisai R&D Man Co Ltd | Composition pharmaceutique pour le traitement de tumeurs |
| US12383557B2 (en) | 2022-04-06 | 2025-08-12 | Genentech, Inc. | Treatment of cancer using combination therapies comprising GDC-6036 and GDC-0077 |
| CR20240508A (es) | 2022-05-19 | 2024-12-20 | Genentech Inc | Compuestos aza-tetracíclicos de oxazepina y usos de los mismos |
| CN115043729B (zh) * | 2022-07-04 | 2024-09-27 | 青岛大学 | 一种2,2’-二氟联芳基化合物的不对称合成方法 |
| IL318647A (en) | 2022-08-05 | 2025-03-01 | Kumquat Biosciences Inc | Heterocyclic compounds and their uses |
| JP2025526744A (ja) | 2022-08-11 | 2025-08-15 | ブリストル－マイヤーズ スクイブ カンパニー | Ｋｒａｓ阻害剤 |
| EP4573095A1 (fr) | 2022-08-17 | 2025-06-25 | Treeline Biosciences, Inc. | Inhibiteurs de pyridopyrimidine kras |
| WO2024081674A1 (fr) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Polythérapies pour le traitement du cancer |
| TW202430179A (zh) | 2022-11-21 | 2024-08-01 | 美商樹線生物科學公司 | 螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑 |
| CN117085515A (zh) * | 2023-01-15 | 2023-11-21 | 安徽科博瑞环境科技有限公司 | 低表面能抗污染中空纤维膜的制备装置 |
| WO2024153119A1 (fr) * | 2023-01-18 | 2024-07-25 | Suzhou Zanrong Pharma Limited | Inhibiteurs de kras g12d et leurs utilisations |
| EP4655298A1 (fr) * | 2023-01-24 | 2025-12-03 | Theras Inc. | Compositions et procédés d'inhibition de ras |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2023439518A1 (en) | 2023-04-06 | 2025-08-28 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
| CN116396202A (zh) * | 2023-04-17 | 2023-07-07 | 南京优氟医药科技有限公司 | 一种（2s，4s）-4-氟代吡咯烷-2-羧酸的制备方法 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| CN121605110A (zh) | 2023-06-06 | 2026-03-03 | 金橘生物科技公司 | 取代杂环化合物及其用途 |
| US20250000802A1 (en) | 2023-06-09 | 2025-01-02 | Hoffmann-La Roche Inc. | Solid formulations comprising an inhibitor of the k-ras protein having a g12c mutation, and a process for preparing |
| WO2025010415A1 (fr) * | 2023-07-05 | 2025-01-09 | The Regents Of The University Of California | Inhibiteurs de gtpase et leurs utilisations |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| TW202529768A (zh) | 2023-09-29 | 2025-08-01 | 大陸商德昇濟醫藥（無錫）有限公司 | 癌症治療的療法 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AU2024361909A1 (en) | 2023-10-20 | 2026-03-26 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2025171296A1 (fr) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025245127A1 (fr) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Inhibiteurs de dihydropyranopyrimidine kras spirocycliques |
| WO2025255438A1 (fr) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras |
| WO2025265060A1 (fr) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Compositions thérapeutiques et procédés de gestion d'effets liés au traitement |
| WO2026006747A1 (fr) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026015790A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026015796A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026015801A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble liés à ras |
| WO2026015825A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas |
| WO2026050446A1 (fr) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026072904A2 (fr) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions et méthodes de traitement du cancer du poumon |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999002557A1 (fr) | 1997-07-11 | 1999-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V | Nouveaux composes pharmaceutiquement actifs entrant en interaction avec des proteines de liaison de gtp |
| CN102131389A (zh) | 2008-06-20 | 2011-07-20 | 健泰科生物技术公司 | 三唑并吡啶jak抑制剂化合物和方法 |
| EP2836482B1 (fr) | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions et méthodes pour le traitement du cancer |
| EP3055290B1 (fr) * | 2013-10-10 | 2019-10-02 | Araxes Pharma LLC | Inhibiteurs de kras g12c |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| WO2016049568A1 (fr) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Méthodes et compositions permettant l'inhibition de la ras |
| JP2017528498A (ja) | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター |
| ES2898765T3 (es) | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| WO2017070256A2 (fr) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Méthode de criblage d'inhibiteurs de ras |
| KR20180081596A (ko) | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| WO2017172979A1 (fr) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Composés quinazoline substitués et procédés d'utilisation |
| KR102444509B1 (ko) | 2016-05-18 | 2022-09-19 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| WO2018218069A1 (fr) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Dérivés de quinazoline utilisés en tant que modulateurs de kras, hras ou nras mutants |
| US10745385B2 (en) | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| CN110869357A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | 化合物及其用于治疗癌症的使用方法 |
| LT3710439T (lt) | 2017-11-15 | 2023-05-10 | Mirati Therapeutics, Inc. | Kras g12c inhibitoriai |
| CN111511729A (zh) | 2017-12-19 | 2020-08-07 | 默克专利股份公司 | Tlr7/8拮抗剂及其用途 |
| TW201942115A (zh) | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
-
2019
- 2019-11-08 PE PE2025003077A patent/PE20260440A1/es unknown
- 2019-11-08 PT PT198428484T patent/PT3735299T/pt unknown
- 2019-11-08 US US16/679,104 patent/US11236068B2/en active Active
- 2019-11-08 HR HRP20241581TT patent/HRP20241581T1/hr unknown
- 2019-11-08 TW TW108140719A patent/TWI784209B/zh active
- 2019-11-08 SG SG11202103298QA patent/SG11202103298QA/en unknown
- 2019-11-08 RS RS20241331A patent/RS66280B1/sr unknown
- 2019-11-08 MA MA51530A patent/MA51530B1/fr unknown
- 2019-11-08 SM SM20240487T patent/SMT202400487T1/it unknown
- 2019-11-08 CN CN201980026181.6A patent/CN112105419B/zh active Active
- 2019-11-08 UA UAA202101478A patent/UA127930C2/uk unknown
- 2019-11-08 ES ES19842848T patent/ES3004042T3/es active Active
- 2019-11-08 JP JP2020542808A patent/JP6941241B2/ja active Active
- 2019-11-08 CN CN202410280943.8A patent/CN118084867A/zh active Pending
- 2019-11-08 IL IL282916A patent/IL282916B2/en unknown
- 2019-11-08 KR KR1020257000144A patent/KR20250012188A/ko active Pending
- 2019-11-08 HU HUE19842848A patent/HUE069365T2/hu unknown
- 2019-11-08 CN CN202410280860.9A patent/CN118084866A/zh active Pending
- 2019-11-08 SI SI201930862T patent/SI3735299T1/sl unknown
- 2019-11-08 EP EP19842848.4A patent/EP3735299B1/fr active Active
- 2019-11-08 EP EP24198360.0A patent/EP4483881A3/fr active Pending
- 2019-11-08 CN CN202410281112.2A patent/CN118084868A/zh active Pending
- 2019-11-08 TW TW111140273A patent/TWI883352B/zh active
- 2019-11-08 PE PE2021000682A patent/PE20211504A1/es unknown
- 2019-11-08 BR BR112021008986-1A patent/BR112021008986A2/pt unknown
- 2019-11-08 DK DK19842848.4T patent/DK3735299T3/da active
- 2019-11-08 FI FIEP19842848.4T patent/FI3735299T3/fi active
- 2019-11-08 KR KR1020237033977A patent/KR102751492B1/ko active Active
- 2019-11-08 AR ARP190103302A patent/AR117194A1/es unknown
- 2019-11-08 CA CA3087089A patent/CA3087089C/fr active Active
- 2019-11-08 WO PCT/US2019/060578 patent/WO2020097537A2/fr not_active Ceased
- 2019-11-08 IL IL311187A patent/IL311187B2/en unknown
- 2019-11-08 MY MYPI2021002582A patent/MY196726A/en unknown
- 2019-11-08 PL PL19842848.4T patent/PL3735299T3/pl unknown
- 2019-11-08 AU AU2019377130A patent/AU2019377130B2/en active Active
- 2019-11-08 CN CN202410281087.8A patent/CN118084870A/zh active Pending
- 2019-11-08 MX MX2021005428A patent/MX2021005428A/es unknown
- 2019-11-08 CR CR20210229A patent/CR20210229A/es unknown
- 2019-11-08 LT LTEPPCT/US2019/060578T patent/LT3735299T/lt unknown
- 2019-11-08 KR KR1020207024122A patent/KR102587544B1/ko active Active
-
2021
- 2021-05-04 CL CL2021001171A patent/CL2021001171A1/es unknown
- 2021-05-07 PH PH12021551065A patent/PH12021551065A1/en unknown
- 2021-05-07 MX MX2025002975A patent/MX2025002975A/es unknown
- 2021-05-07 MX MX2025002979A patent/MX2025002979A/es unknown
- 2021-05-07 MX MX2024008118A patent/MX2024008118A/es unknown
- 2021-05-07 CO CONC2021/0005987A patent/CO2021005987A2/es unknown
- 2021-05-07 MX MX2025002980A patent/MX2025002980A/es unknown
- 2021-07-15 JP JP2021116809A patent/JP7374960B2/ja active Active
- 2021-12-17 US US17/644,993 patent/US12084429B2/en active Active
-
2022
- 2022-03-01 AU AU2022201413A patent/AU2022201413B9/en active Active
- 2022-03-22 CL CL2022000698A patent/CL2022000698A1/es unknown
-
2023
- 2023-10-25 JP JP2023183500A patent/JP7579414B2/ja active Active
-
2024
- 2024-02-13 AU AU2024200904A patent/AU2024200904B2/en active Active
- 2024-06-18 US US18/747,054 patent/US20250059163A1/en active Pending
- 2024-10-25 JP JP2024187827A patent/JP2025026853A/ja active Pending
-
2025
- 2025-10-20 IL IL324078A patent/IL324078A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51530A (fr) | Composés cycliques fondus | |
| EP3836923A4 (fr) | Composés pyrrolo-dipyridine | |
| MA52948A (fr) | Composés | |
| EP3802467A4 (fr) | Composés spirocycliques | |
| MA52489A (fr) | Nouveaux composés | |
| EP3781156A4 (fr) | Composés spirocycliques | |
| MA51669A (fr) | Composés | |
| EP3941898C0 (fr) | Composés fongicides | |
| EP3746436A4 (fr) | Composés cycliques condensés | |
| EP3956033A4 (fr) | Composés bicycliques | |
| EP3720430A4 (fr) | Composés benzocarbonyle | |
| MA55131A (fr) | Nouveaux composés hétérocycliques | |
| EP3691623A4 (fr) | Composés de benzosulfonyle | |
| MA53003A (fr) | Composés | |
| MA52560A (fr) | Composés hétéroaryles tétracycliques | |
| EP3740487A4 (fr) | Composés benzamide | |
| EP3558322A4 (fr) | Composés benzyl-amide phosphodiamide antiviraux | |
| EP3532069A4 (fr) | Composés aryl-amide phosphodiamide antiviraux | |
| MA44233A (fr) | Nouveaux composés | |
| PT3774862T (pt) | Novos análogos de glp-1 | |
| EP3853210A4 (fr) | Composés antibactériens | |
| MA50504A (fr) | Composés antibactériens | |
| MA52946A (fr) | Composés | |
| MA45221A (fr) | Nouveaux composés antibactériens | |
| EP3728289A4 (fr) | Composés optimisés |